Weigh! 128 products purchased with quantity

▍ source: Anhui yaozhengjun / sabilan ▍ Author: Yuanwang ▍ purchasing and expanding varieties with quantity, 128 Recently, at the Symposium of pharmaceutical enterprises held by Anhui Medical Insurance Bureau, relevant leaders of Anhui Medical Insurance Bureau made public the implementation plan of negotiation and negotiation (pilot) for the purchase of some commonly used clinical drugs and the second batch of anticancer drugs in public medical institutions affiliated to Anhui Province It is reported that the main contents of the scheme are as follows: 1 After the successful pilot implementation of public medical institutions affiliated to Anhui Province, it is gradually promoted to all public medical institutions above the county level in Anhui Province (the promotion time may be within a quarter, that is, before New Year's Day 2020), and other medical institutions are encouraged to cooperate, with a procurement cycle of one year 2 In 2018, antibiotics, i.e cephalosporin related drugs, were purchased from public medical institutions in Anhui Province 90% of the chemical drugs for regulating lipids and 80% of the chemical drugs for the second batch of anti-cancer and anti-tumor drugs were selected and purchased in volume According to the clinical drug use and quality type factors, the list was selected by medical experts It is reported that up to now, the list of drugs purchased with volume has been preliminarily determined, involving 128 drugs in total, which is not suitable for public announcement for the time being 3 Make clear the negotiation price with centralized carrying capacity and the shortlist price of negotiation price - the shortlist price refers to the lowest price of the provincial bidding price since 16 years or the median price and the lowest price of the actual purchase price of the provincial public medical institutions in 18 years, as well as the first price of the two vote system When Anhui Medical Insurance Bureau responded to the drug companies, it also made clear that the entry price for negotiation was the threshold, and it would inform the drug companies in advance The drug companies that did not meet the entry price will not accept their registration and participate in the negotiation 4 The total purchase amount is 60% - 70% of the reported amount of public medical institutions affiliated to Anhui Province in 2018 annual report, which is the total purchase amount to carry out volume purchase and sign a contract to ensure that the consumption is completed within one year Guarantee the payment, forbid the second negotiation, and complete the payment within 90 days According to the on-site response of Anhui Medical Insurance Bureau, there will be two rounds of negotiation and price comparison, and the share of unsuccessful manufacturers in the two rounds of negotiation will be divided into 1-3 successful ones, and the purchase volume of selected pharmaceutical companies may surge 5 If the negotiation fails, all specifications of the same package of the same dosage form of the same generic name of the enterprise shall be listed in the key monitoring directory for key monitoring Anhui Medical Insurance Bureau responded that non winning products are not non prescription, but will be listed in the key monitoring directory for key monitoring 6 The successful negotiation can save money in two parts: 50% is used to reduce the drug payment standard, reduce the expenditure of medical insurance fund, and reduce the burden of patients' medication; 50% is used to encourage provincial public medical institutions This requirement will undoubtedly greatly enhance the enthusiasm of Anhui provincial medical institutions to participate in volume procurement ▍ the negotiation was not successful It is not difficult to see the key monitoring from the above scheme In combination with the drug use situation of public medical institutions in Anhui Province, the rules of the pilot scheme of centralized drug volume procurement organized by the State - procurement cycle of one year, negotiation and negotiation for procurement, determination of procurement volume, guarantee of payment back, have taken the lead in the expansion of volume procurement in Anhui Province In addition, on the basis of the pilot program of centralized drug volume procurement organized by the state, Anhui further proposed that the same generic drugs with unsuccessful negotiation, the same dosage form, the same packaging and all specifications were included in the key monitoring To a certain extent, this regulation not only puts pressure on pharmaceutical enterprises participating in the volume purchase in Anhui Province to win the selection, but also ensures that the use of the selected drugs in the future will not be affected by the unselected drugs, and prevents the low-cost drugs from being squeezed by the high-cost drugs In addition, on the spot of the symposium, Anhui Medical Insurance Bureau also made a series of responses to the relevant suggestions of pharmaceutical enterprises - for example, Anhui Medical Insurance Bureau made it clear that it would protect the bidding price and not publicize it to the public, which would reduce the price pressure of pharmaceutical enterprises to a certain extent and protect the price system of pharmaceutical enterprises It is worth noting that Anhui Medical Insurance Bureau has repeatedly stressed that it is impossible not to reduce the price It is hoped that in the future, it can continuously select the varieties that occupy the medical insurance fund to purchase again with volume From the above sentence, it is not difficult to see that the mechanism of centralized volume purchase of drugs will continue to be used, and more varieties will continue to be included in volume purchase Specifically, in the list of Medicare drugs, the varieties whose purchase amount occupies more medical insurance funds may be included in volume purchase The second batch of ▍ 4 + 7 was expanded rapidly According to Anhui Medical Insurance Bureau, the selection of the list of products purchased with quantity has been completed, basically eliminating exclusive products It is worth noting that the products purchased with quantity in Anhui do not contain the products with consistency evaluation The relevant leaders of Anhui medical insurance bureau are clear that the drugs with consistency evaluation are purchased with quantity centralized by the state organization Since the 4 + 7 pilot project was officially expanded to the whole country, it is generally believed in the industry that the next step is to expand varieties after 25 varieties expansion regions There is even news that by the end of the year, the second batch of products purchased with volume will be announced According to industry commentators, at present, there are two ways to expand varieties: bottom-up and top-down The bottom-up route refers to that since the 4 + 7 pilot project has been passed, the scheme of volume purchase, specific implementation rules and experience are available In order to save medical insurance funds and reduce the burden of patients, the medical insurance bureaus in those provinces and cities have full motivation to carry out volume purchase for the drugs with large clinical dosage in their own provinces and cities in combination with the actual drug use in their own regions, and these departments The 4 + 7 varieties included in the scope of volume procurement by provinces and cities deserve the attention of the pharmaceutical industry The top-down route is mainly led by the joint procurement office under the Shanghai Medical Insurance Bureau, which selects varieties in 4 + 7 pilot cities and even across the country to carry out a new round of volume procurement At this time, due to the large number of regions involved, the selected varieties will be more universal, and it is still necessary to consider that more than three pharmaceutical enterprises have been evaluated for consistency According to Guotai Junan's early review, in addition to the 25 varieties collected in the first batch (in common name), another 97 varieties (in common name) (deemed as same) passed the consistency evaluation before the deadline Among them, 31 varieties have more than or equal to 3 enterprises meeting the conditions of centralized mining (original research or through evaluation); 47 varieties have 2 enterprises meeting the conditions of centralized mining; 19 varieties have only 1 enterprise meeting the conditions of centralized mining It is expected that the second batch of varieties to be collected will be selected from these varieties, especially those with large market scale and large number of enterprises (photo source: Guotai Junan Securities)